High activity fusion construct of human soluble TRAP/CD40L is a Human protein, in the 116 to 261 aa range, expressed in CHO, with >90% purity, < 0.1 EU/µg endotoxin level and suitable for SDS-PAGE, FuncS.
>90% SDS-PAGE
< 0.1 EU/µg
CHO cells
DDDDK tag N-Terminus
SDS-PAGE, FuncS
Yes
G D Q N P Q I A A H V I S E A S S K T T S V L Q W A E K G Y Y T M S N N L V T L E N G K Q L T V K R Q G L Y Y I Y A Q V T F C S N R E A S S Q A P F I A S L C L K S P G R F E R I L L R A A N T H S S A K P C G Q Q S I H L G G V F E L Q P G A S V F V N V T D P S Q V S H G T G F T S F G L L K L
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application FuncS | Reactivity Reacts | Dilution info - | Notes - |
Select an associated product type
Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973). Costimulates T-cell proliferation and cytokine production (PubMed:8617933). Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933). Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973). Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037). Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037). Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity).CD40 ligand, soluble formActs as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling.
CD40L, TNFSF5, TRAP, TRAP, TNFSF5, CD40L, CD40LG, CD40 ligand, CD40-L, T-cell antigen Gp39, TNF-related activation protein, Tumor necrosis factor ligand superfamily member 5, TRAP
High activity fusion construct of human soluble TRAP/CD40L is a Human protein, in the 116 to 261 aa range, expressed in CHO, with >90% purity, < 0.1 EU/µg endotoxin level and suitable for SDS-PAGE, FuncS.
>90% SDS-PAGE
< 0.1 EU/µg
CHO cells
DDDDK tag N-Terminus
SDS-PAGE, FuncS
Yes
ab168061 binds to Human CD40.
ab168061 induces B cells activation (as demonstrated by dose-dependent upregulation of CD86).
No
Yes
Human
Reconstitute in 100 µL of water
Constituents: 99% PBS
G D Q N P Q I A A H V I S E A S S K T T S V L Q W A E K G Y Y T M S N N L V T L E N G K Q L T V K R Q G L Y Y I Y A Q V T F C S N R E A S S Q A P F I A S L C L K S P G R F E R I L L R A A N T H S S A K P C G Q Q S I H L G G V F E L Q P G A S V F V N V T D P S Q V S H G T G F T S F G L L K L
38 kDa
116 to 261
Recombinant
DDDDK tag N-Terminus
Lyophilized
ab168061 is purified by multi-step chromatography.
Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973). Costimulates T-cell proliferation and cytokine production (PubMed:8617933). Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933). Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973). Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037). Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037). Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity).
Belongs to the tumor necrosis factor family.
The soluble form derives from the membrane form by proteolytic processing.
Blue Ice
-20°C
-20°C
This product is an active protein and may elicit a biological response in vivo, handle with caution.
ab168061 is a high-activity construct in which two trimeric CD40L molecules are artificially linked via the collagen domain of Adiponectin. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo.
This supplementary information is collated from multiple sources and compiled automatically.
TRAP/CD40L also known as CD154 or CD40 ligand is a type II transmembrane protein with a molecular mass of approximately 39 kDa. CD40L is mainly expressed on the surface of activated T cells. This protein binds to CD40 a significant receptor present on several immune cells including B cells macrophages and dendritic cells. The interaction with CD40 is essential for immune cell activation and development marking CD40L as an important player in adaptive immunity.
The interaction between CD40L and CD40 triggers cell proliferation differentiation and apoptosis in immune cells. CD40L contributes to the formation of an immunological synapse encompassing its role in T helper cell function. Furthermore CD40L is implicated in the activation of B cells which are necessary for antibody class switching and memory cell generation. Its broad influence shows CD40L's involvement in immune system regulation and response.
CD40L is integral to the CD40 signaling pathway which is involved in immune and inflammatory responses. CD40L activates the NF-kB and JNK signaling pathways by engaging with CD40 which then drives the transcription of genes related to immune response. This signaling cascade impacts several other proteins such as TRAF proteins which act as intermediaries in propagating the signal.
CD40L has been linked to immune-related conditions including autoimmune disorders and inflammatory diseases. Elevated CD40L expression is observed in diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. In SLE CD40L interaction with CD40 on B cells is known to exacerbate disease severity by promoting autoantibody production. Exploring anti-CD40L therapeutic strategies can offer potential intervention in such diseases.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
SDS-PAGE analysis of ab168061.
B cell lymphocyte activation by ab168061. Method: Peripheral Blood Mononuclear Cells (PBMCs) were incubated at 37°C, 5% CO2 for 48 hours in 48 well plates (1 x 106 cells/well). Each well contained 200µl serum free test media with serially diluted ab168061. After treatment, cells were washed and dual-stained with mouse anti-human CD19–PE and mouse anti-human CD86–APC and analyzed by flow cytometry. The data are presented as the percent of CD19 positive B cells that co-stain as CD86 positive, at each concentration of ab168061.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com